CANImmunize

The Canadian Vaccine Catalogue

Working Group Meeting

January 13, 2022

Agenda

1. Welcome
2. COVID-19 Terminology Discussion
   a. Pfizer BioNTech Comirnaty tris-sucrose, 12+
   b. Moderna pediatric dose
3. Other RFCs
4. SNOMED-CT updates and CVC data quality
5. Release summary
6. Wrap up and questions

2a. Pfizer-BioNTech COMIRNATY - Tris-Sucrose

- Pfizer has not yet submitted an application for this formulation yet
- Health Canada will provide an update once submission is received
- Canada Health Infoway will process the RFC next week

CVX	Concept Code (SNOMED: Concept ID)	Proposed concept name (SNOMED: FSN)	Display name (SNOMED: Preferred Term)	Public Trade name Picklist (CVC specific)	Clinician Trade name Picklist (CVC specific)	Generic agent abbreviation	Generic agent parent concept code
217[1]	Not created	COMIRNATY vaccine messenger ribonucleic acid 30 micrograms per 0.3 milliliter tris-sucrose buffer suspension for injection BioNTech Manufacturing GmbH (real clinical drug)	COVID-19 COMIRNATY tris-sucrose mRNA PB	Pfizer-BioNTech Comirnaty tris-sucrose COVID-19 mRNA	Pfizer-BioNTech Comirnaty tris-sucrose (COVID-19)	COVID-19	1119349007 (COVID-19 mRNA)

[1] Source: CDC (https://www.cdc.gov/vaccines/programs/iis/COVID-19-related-codes.html)

2b. Moderna Spikevax pediatric dose

Product details that have been confirmed with Health Canada:

Trade Name	Spikevax (elasomeran mRNA vaccine)
Strength	• NACI recommended: Some adult booster dose: 50 micrograms/0.25 mL dose • Not yet HC approved: Age 6 – 11 years: 50 micrograms/0.25 mL dose (*i.e. the presentation is unchanged from the approved NOC: 200 mcg/mL)*
Dose form	Dispersion for injection
Marketing Authorization Holder (MAH)	ModernaTx, Inc.
DIN	Same as adult
CVX	207 (unchanged)

Outreach to PHAC still in progress on how pediatric doses will be tracked.

- **Update:** Health Canada has asked for more data on lower dose. May be a modification of strength.

3. Other RFCs - HyperTET (request from BC)

Concept Code (SNOMED: Concept ID)	Proposed concept name (SNOMED: FSN)	Display name (SNOMED: Preferred Term)	Public Trade name Picklist (CVC specific)	Clinician Trade name Picklist (CVC specific)	Generic agent abbreviation	Generic agent parent concept code
Not created	HyperTET 250 antitoxin units per milliliter solution for injection Grifols Canada Limited	Tlg HyperTET Grif	HyperTET	HyperTET (Tlg)	Tlg	86337009 (Tetanus immunoglobulin)

- The display term for existing concept 7981000087105 |HYPERTET S/D 250 units per dose solution for injection Grifols Canada Limited (product)| is currently "Tlg HYPERTET Grif" - RFC to be submitted to add S/D to distinguish from the above concept.
- Additionally, DIN for this concept in CVC is listed as 02379619. Should it be updated to 02230697? Source: https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
    - Helen to confirm

4. SNOMED-CT Updates and CVC Data Quality

Subset	Change
Generic	• Inactivated concepts: 69 • New concepts: 51 • Changes in concept name: All except 5 concepts ("Vaccine product containing only…") • Changes in English display name: 1 concept • Changes in French translation: 3 concepts
Tradename	• Inactivated concepts: 16 • New concepts: 8 • Changes in concept name: All except 24 concepts (majority being semantic tag) • Changes in English display name: 1 concept • Changes in French translation: 4 concepts
Disease	• Inactivated concepts: 2 • New concepts: 1 • Changes in French translation: 1 concept
Antigen/Antitoxin	• Inactivated concepts: 1 • New concepts: 18 • Changes in concept name: All except 16 concepts • Changes in English display name: 2 concepts • Changes in French translation: 11 concepts • Request for French translation: 1 concept

4. SNOMED-CT Updates and CVC Data Quality

Inactivated	New Concept
Concept Code: 3526007 Concept Name: Rabies vaccine, human (product) - Imovax Rabies 2.5 international units per milliliter powder for solution for injection Sanofi Pasteur Limited (product) - RABAVERT 2.5 international units per milliliter powder for solution for injection Bavarian Nordic A/S (real clinical drug) - RabAvert 2.5 international units per milliliter powder for solution for injection GlaxoSmithKline Inc. (real clinical drug) - RabAvert 2.5 international units per milliliter powder for solution for injection Novartis Vaccines and Diagnostics Gmbh (product)	Concept Code: 871726005 Concept Name: Vaccine product containing only Rabies lyssavirus antigen (medicinal product) - Imovax Rabies 2.5 international units per milliliter powder for solution for injection Sanofi Pasteur Limited (real clinical drug) - RABAVERT 2.5 international units per milliliter powder for solution for injection Bavarian Nordic A/S (real clinical drug) - RabAvert 2.5 international units per milliliter powder for solution for injection GlaxoSmithKline Inc. (real clinical drug) - RabAvert 2.5 international units per milliliter powder for solution for injection Novartis Vaccines and Diagnostics Gmbh (real clinical drug)

4. SNOMED-CT Updates and CVC Data Quality

Next steps

- CVC team to prepare delta file with what is currently in the CVC and what proposed changes are, by concept, and share with stakeholders early next week
    - Includes proposing new generic parent ID mapping in for each trade name product where applicable (as many concepts were inactivated)

5. Release Summary - Version 1.1.16

Lot/expiry information

- All vaccines - December, January
- COVID-19 vaccines - most up to date

Tradename subset

- Addition of HyperTET (pending concept creation)
- Modification of existing HyperTET S/D Preferred Term/DisplayTerm and DIN

Target release date: early February

6. Wrap up and Questions

- Next CVC Meeting
  - Tuesday, February 15th, 2022 from 2-3PM EST
  - Register in advance for this meeting: https://infoway-inforoute.zoom.us/meeting/register/tZYkduCurD0qHtKYuK6SLujC3ZTJdNkJGVPq